The intracellular signalling molecule cGMP regulates a variety of physiological processes; hence monitoring cGMP dynamics in living cells is highly desirable. Here, we report a systematic approach to create fluorescence resonance energy transfer (FRET)-based cGMP indicators from the two known types of cGMP-binding domains, cNMP-BD and GAF, found in cGMP-dependent protein kinase and phosphodiesterase 5, respectively. Interestingly, only cGMP-binding domains arranged in tandem configuration as in their parent proteins were cGMP-responsive, however, the GAF-derived sensors had to be discarded because of slow kinetics. Out of 24 cGMP-responsive constructs derived from cNMP-BDs, three were selected to cover a range of cGMP affinities with half maximally effective concentrations between 500 nM and 6 µM. These indicators feature excellent cGMP specificity, fast kinetics and twice the dynamic range of existing cGMP sensors. The in vivo performance of the new indicators is demonstrated in living cells and validated by comparison with cGMP dynamics measured by radioimmunoassays.
INTRODUCTION
The second messenger cGMP is involved in a variety of physiological processes in mammals, especially in the nervous and vascular systems. Here, cGMP mediates smooth muscle relaxation, inhibition of platelet aggregation and modulation of synaptic plasticity [1] [2] [3] [4] [5] . cGMP signals elicited by hormonal stimulation in a given tissue are determined by the cGMPgenerating and -degrading enzymes present. Two families of cGMP-generating enzymes exist, the peptide receptor guanylyl cyclases (GC), membrane spanning enzymes activated by peptide hormones like the atrial natriuretic peptide, and the nitric oxide receptor GC activated by the short-lived messenger nitric oxide [6] [7] [8] [9] [10] . On the other hand, several families of differentially regulated cGMP-degrading phosphodiesterases are known [11, 12] , e.g. PDE1 is stimulated by Ca ++ whereas PDE5 is activated by its substrate cGMP. The given combination of GCs and PDEs within specific cell types and even subcellular compartments therefore critically determines amplitude and shape of cGMP signals. The cellular effects of cGMP are conveyed by cGMP-dependent protein kinases [13] [14] [15] , cGMP-regulated ion channels [16] and by cGMP-regulated phosphodiesterases [1, 12] .
With established techniques, the biological effects of cGMP, such as blood vessel relaxation, can be recorded continuously, whereas the cGMP signals themselves can not. Currently, cGMP signals can only be measured subsequent to lysis of cells or tissues by radioimmunoassay (RIA) or enzyme linked immunosorbent-assay (ELISA) using antibodies against cGMP. Hence, a temporal resolution requires determination of tissue cGMP contents at several consecutive time points. Acquiring time courses in this way is laborious, therefore the vast majority of cGMP values reported in the literature were obtained at a single time point, typically as late as 10 minutes after stimulation of the cells or tissues.
On the other hand, accumulating evidence suggests that cGMP signals are of a rather fast and transient nature. Back in 1975, Matsuzawa and Nirenberg [17] reported N1E-115 neuroblastoma cells to respond to carbamylcholine stimulation with a transient up to 200-fold increase in cGMP that lasted for less than 2 minutes. These rapid cGMP kinetics were later confirmed using membrane patches with cyclic nucleotide gated channels crammed into N1E cells [18] . Platelets displayed even faster cGMP signals upon NO stimulation that peaked within 10 s and returned to baseline within 30 s [19, 20] . Thus, indicators that allow continuous monitoring of cGMP concentrations in living cells will substantially improve our knowledge of cyclic nucleotide signalling.
To date, three attempts were made to develop such cGMP indicators. All contained a cGMPbinding domain sandwiched between two fluorescent proteins [21, 22] monophosphate binding domain, is conserved in the cGMP-dependent protein kinases (cGK) and the cGMP-regulated ion channels [13, 14] . The second, dubbed GAF domain abbreviating the three proteins in which it was first identified, is in mammals exclusively found in PDEs [23, 24] . Interestingly, two of the cNMP-BD or GAF domains are arranged in tandem in the cGK and PDE, respectively. In cGKI, the N-terminal cNMP-BD, designated cNMP-BD A, has been described as high affinity site whereas cNMP-BD B has a rather low cGMP affinity [25, 26] . In PDE5, the N-terminal GAF domain, GAF-A, binds cGMP leading to activation of the enzyme [27, 28] .
The first two cGMP sensors published five years ago used almost the complete cGKI containing both cNMP-BDs lacking only the dimerization domain (47 or 78 amino acids) [29, 30] . Recently, a new attempt was made to generate simpler sensors using a single cNMP-BD from cGKI or a single GAF domain of PDE 2 or 5 [31] (see Fig. 1 ). The authors reported that only the PDE5 GAF construct responded sufficiently fast for monitoring intracellular cGMP signals.
Taken together, only limited efforts have been made to create cGMP indicators. On one hand, complete cGKs have been used raising the question about the purpose of the catalytic domains in the indicator. On the other hand, only single cGMP-binding domains were tested, albeit both the cGK and PDE each contain these domains in tandem.
Here, we describe a systematic approach to design cGMP indicators using the single and tandem cGMP-binding domains of cGKI (cNMP-BD) and PDE5 (GAF). More than 50 constructs containing different regions of these domains were generated and tested in vitro. Based on these data, three indicators containing the tandem cNMP-BD exhibiting cGMP affinities between 500 nM and 6 µM were chosen to span a range of cGMP concentrations. The in vivo performance of the new indicators is demonstrated by simultaneous measurements of cGMP signals with the new cGMP indicators and radioimmunoassays. Tables   1 and 2 were amplified by PCR and subcloned into pcDNA3 containing the coding region of CFP (Clontech's ECFP, equivalent to variant 10C [32] , C-terminally truncated at Ala 228 , see below) and YFP (Clontech's EYFP, equivalent to variant W1B [32] ), using the type IIa restriction endonuclease Esp3I. In the resulting protein sequence, the cGMP-binding domain (see. Tabs. 1 and 2) is directly preceded by the C-terminal end of CFP (…Thr 226 Ala 227 Ala 228 -) and followed by YFP (-Met 1 Val 2 Ser 3 …) without any additional amino acids, respectively. To allow screening of a larger number of constructs, only some of them were verified by sequencing (showing no mutations at all).
MATERIALS AND METHODS

Construction of the sensors. DNAs encoding the cGMP-binding domains as listed in
In vitro characterization. The indicators were transiently expressed in HEK-293 cells using Fugene6 according to the manufacturer's instructions (Roche). Transfected cells (1 × 10 7 ) were harvested and lyzed in homogenization buffer (50 mM NaCl, 1 mM EDTA, 50 mM triethaolamine/HCl, pH 7.4, containing 2 mM dithiothreitol and a 100-fold dilution of protease inhibitor cocktail, Sigma-Aldrich) by sonication (1 pulse, 5 s). A cytosolic fraction was obtained (100,000 × g, 30 min, 4 °C) and emission spectra were recorded using a Cary eclipse spectrofluorometer (Varian Inc., excitation at 436 nm). In brief, 10 to 100 µl of the cytosol containing the indicators were measured in a total volume of 800 µl buffer A (25 or In vivo measurements. HEK-293 cells stably expressing the NO receptor GC and PDE5 were cultured as described [33] . Measurements were performed at room temperature after replacing the cell culture medium by PBS. Cells were stimulated with DEA-NO (200 µM) and YC-1 (20 µM) at the time points indicated and subsequently cGMP contents were determined by RIA as described [33] . For fluorescence microscopy, the cells were grown on coverslips and transfected with the indicators as described above. After mounting the coverslips onto the microscope stage, cells were maintained at room temperature in PBS and stimulated as 
RESULTS
To generate genetically encoded indicators for cGMP measurements in living cells, different cGMP-binding domains were sandwiched between two fluorescent proteins, CFP and YFP.
PDE5-derived constructs are too slow for detection of cGMP signals
First, we tried to design cGMP indicators from PDE5 using the single GAF A as well as the tandem of GAF A + B (see Fig. 1 ). Our attempt to select regions according to the crystal structure of the PDE2 GAF domains [34] Therefore, PDE5-GAF A + B, N-terminally elongated by 51 amino acids and C-terminally shortened by 2 amino acids, (see Tab. 1) was further characterized. First, concentration response curves of the construct were obtained yielding an apparent EC 50 of 0.3 µM cGMP ( Fig. 2A ). The construct was selective for cGMP; up to 100 µM of cAMP did not elicit a FRET change (see Fig. 2A ). However, while recording the cGMP concentration response curves, we realized that the construct responded rather slowly to low concentrations of cGMP.
Thus, kinetics of cGMP binding were assessed ( 
cGMP indicators derived from cGK display fast kinetics
Next, we reevaluated the already existing cGMP sensors containing almost the complete cGKI [30] and found much faster binding kinetics than with the GAF constructs in vitro (not shown). Therefore, we decided to construct cGMP indicators from the cNMP-BD of cGKI.
The margins of the cNMP-BD were deduced from the cAMP-binding domains of the cAMPdependent protein kinase crystallized 10 years ago [35] . To circumvent extremely low cGMP affinities, we used cGKI's high affinity cNMP-BD A [25, 26] and the tandem of cNMP-BD A + B for construction of the indicators (see Fig. 1 ). As described for the GAF domains of PDE5, we screened for cGMP-induced FRET changes and characterized functional, cGMPresponsive constructs with regards to cGMP affinity (Tab. 2). As with the GAF domains, the single cNMP-BD A did not produce functional indicators. However, constructs composed of both cNMP-BD A + B responded to cGMP with an up to 80% increase in CFP/YFP emission ratio. Based on cGMP affinity and extent of FRET change, three cGMP indicators were selected covering a range of half maximally effective cGMP concentrations of 500 nM, 3 µM and 6 µM and termed cGi-500, cGi-3000 and cGi-6000, respectively (Fig. 3A) . cGi-500 and cGi-3000 responded with pronounced FRET changes (77% and 72% increase, respectively), whereas cGi-6000 had a somewhat lower dynamic range of 57%. The constructs were highly selective for cGMP, up to 1 mM cAMP elicited only marginal emission increases ( Fig. 3B ).
Next, we assessed the binding and dissociation kinetics. Using stopped flow instrumentation with a dead time of 80 ms, we were not able to monitor binding kinetics, i.e. binding was complete within the dead time of the instrument (not shown). As with the GAF constructs, dissociation was characterized by a 100-fold dilution of the cGMP-bound indicators. In contrast to the GAF construct (see Fig. 2C ), dissociation was complete within the mixing time 
The new cGMP indicators detect cGMP signals in vivo
HEK293 cells stably expressing NO-sensitive GC and PDE5 [33] were used to demonstrate the in vivo performance of the cGMP indicators. These cells show transient up to 300-fold cGMP increases upon NO application that are reversible within 5 min as demonstrated by cGMP measurements in radioimmunoassays (Fig. 4A ). The cGMP signals in these cells are reminiscent of those in platelets and smooth muscle cells, which also show several ten fold increases in cGMP that rapidly return to almost basal levels within seconds to minutes [19] .
Since sustained activation of PDE5 outlasts the cGMP signals by far, the cells can not be restimulated with NO. However, YC-1, a combined GC activator and PDE inhibitor [36, 37] , overcomes the activation of PDE5 and again increases cGMP levels (see Fig. 4A ). Supplementary Video 1) . Thereafter, the cGMP levels declined (see Fig. 4A ) and the indicators followed that decline according to their cGMP affinities, i.e. the most sensitive indicator, cGi-500, displayed a minor decrease in emission ratio, whereas the indicator with the lowest affinity, cGi-6000 decreased to almost basal level (see Figs. 4B and D) . The subsequent cGMP elevation elicited by YC-1 (see Fig. 4A ) is reflected by the three indicators and again saturated cGi-500 and -3000.
In order to calibrate the obtained FRET signals to cGMP concentrations, we considered the application of membrane permeable cGMP analogues. We first ensured that the cGMP analogues bind to the cGMP indicators and generate FRET changes comparable to cGMP by in vitro analysis (not shown). Then, we applied the cGK activators to the HEK cell line and recorded the CFP/YFP emission ratio as described above for For this purpose, cGMP-binding domains were sandwiched between two fluorescent proteins (see Fig. 1 ). Two substantially different cGMP-binding domains are known. The first one, cNMP-BD, is conserved in the cGK and the cGMP-regulated ion channels. The second one, GAF, is in mammals found in PDEs.
Because earlier indicators derived from the cGKI apparently had a low temporal resolution [30] , we first tried to use GAF domains for development of cGMP indicators. The GAF domains of PDE5 were selected because among the PDE GAF domains they show the highest specificity for cGMP vs. cAMP. We generated a series of constructs from the single GAF A domain; however, none of these constructs showed cGMP-induced FRET changes.
Furthermore, a range of constructs containing the tandem of GAF A + B was characterized.
Interestingly, solely constructs containing not only the two GAF domains but also the PDE5 phosphorylation site located 42 amino acids N-terminally of the GAF domains showed cGMP-induced conformational changes. The requirement for the phosphorylation site is not obvious; together with biochemical data from the holoenzyme these findings suggest that the phosphorylation site is in close proximity to the GAF domains and released upon cGMP binding [28] . Disappointingly, the conformational changes of these GAF-derived constructs were rather slow. At 100 nM cGMP, completion of the FRET change took more than a minute. More than an hour was required for cGMP dissociation. Such slow kinetics renders the constructs inappropriate for monitoring intracellular cGMP signals that are much faster.
Therefore, we decided to create constructs from the other type of cGMP-binding domains, the Both cNMP-BD were required to obtain cGMP-responsive constructs. In the cGK holoenzyme, both sites have been shown to bind cGMP. While the sites have different affinities and exhibit cooperativity in cGKIα, the matter is controversial for cGKIβ [38, 39] .
The N-terminal parts preceding the cNMP-BD are the only regions differing between cGKIα and β and have been shown to be responsible for the different cGMP binding properties [39, 40] . Furthermore, proteolytic removal of cGKIα amino acids preceding Gln 79 has been described to eliminate cooperativity [41] . concentration of the biomolecule to be measured has to be clamped to low and high concentrations; together with the EC 50 of the indicator obtained in in vitro experiments, the intracellular concentration of the biomolecule can be calculated. For Ca 2+ indicators this type of calibration is performed by using chelators and ionophores, however similar tools for the manipulation of cyclic nucleotide levels inside cells are not available. Therefore, the use of activators and inhibitors of cGK, i.e. agonists and antagonists of the cNMP-BD, appeared to be the only way to force the cGMP indicators to the cGMP-bound and -free states. We tested several membrane permeable analogues but apparently the intracellular concentrations reached were not sufficient to elicit FRET responses. Physiological responses to these membrane permeable activators are well established. Therefore, this result was unexpected but can be explained by the fact that physiological responses already occur at low intracellular concentrations leading to activation of only some cGK molecules, whereas a substantial portion of the FRET indicators molecules has to become bound to produce a detectable FRET signal.
FRET-based indicators for intracellular cGMP have been constructed before. The 'cygnet' [30] and 'cgy' [29] sensors described 5 years ago contained almost the complete cGK which positioned the fluorophores in larger distance resulting in smaller FRET changes compared to the indicators described here (see Fig. 1 and Tab. 3). It remains unclear why deletion of the kinase catalytic domain was described to cause irreversible FRET changes upon cGMP binding [30] as this was not the case in our hands. Recently, a sensor, termed cGES-DE5, made up of the GAF A domain of PDE5 was published to have superior properties compared to the cygnet sensors [31] . Although our GAF A constructs differ by less than 10 amino acids from the cGES-DE5, they showed negligible cGMP-induced FRET changes. Furthermore, our functional constructs containing the tandem GAF A + B domains of PDE5 had rather slow kinetics. The reasons for these discrepancies are unknown and may be attributed to the differences between the constructs. However, the fluorescence emission spectra of cGES-DE5
published (Supplement to [31] ) indicate an only 20% change in the uncorrected emission ratio in response to cGMP (see Tab. 3).
Taken together, in a systematic approach the two known types of cGMP-binding domains were tested for their suitability to serve as cGMP indicators by fusing different fragments of the domains to two fluorescent proteins. Constructs containing GAF domains of PDE5 exhibited extremely slow binding and dissociation kinetics. Three cGMP indicators based on the tandem of cNMP-BD A + B of cGK were generated that respond fast and reversibly to cGMP, display a high specificity for cGMP over cAMP and cover a range of cGMP affinities between 500 nM and 6 µM. With the help of these indicators, physiologically relevant cGMP signals that remain undetected with current techniques will be unveiled as will be cGMP signals in subcellularly confined signalling microdomains. Table 2 FRET constructs derived from the cNMP-BD of cGKI 
